HUE031208T2

HUE031208T2 - Bendamusztin kiszerelései

Info

Publication number: HUE031208T2
Application number: HUE11737745A
Authority: HU
Inventors: Nagesh R Palepu; Philip Christopher Buxton
Original assignee: Eagle Pharmaceuticals Inc
Priority date: 2010-01-28
Filing date: 2011-01-28
Publication date: 2017-07-28
Also published as: SMT201700043B; SI3158991T1; DK2528602T4; EP2528602B1; US20160143888A1; US20190350904A1; ES2609106T3; US20210393594A1; JP2013518130A; US20230115164A1; HRP20210915T1; CA2787568C; WO2011094565A1; CY1124262T1; RS55491B1; US9572796B2; EP3158991B1; US20110184036A1; HUE054836T2; ES2609106T5

Description

(12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 311415 <200601> A61K 47110 <200601) 05.10.2016 Bulletin 2016/40 A61K 47Ι2Ο<2006 01> A61K 9I08<2006 01> (21) Application number: 11737745.7 (86) International application number: PCT/US2011/022958 (22) Date of filing: 28.01.2011 (87) International publication number: WO 2011/094565 (04.08.2011 Gazette 2011/31)

(54) FORMULATIONS OF BENDAMUSTINE

FORMULIERUNGEN AUS BENDAMUSTIN FORMULATIONS DE BENDAMUSTINE (84) Designated Contracting States: (74) Representative: Capasso, Olga

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB De Simone & Partners SpA GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Via Vincenzo Bellini, 20 PL PT RO RS SE SI SK SM TR 00198 Roma (IT) (30) Priority: 28.01.2010 US 299100 P (56) References cited: WO-A1-2010/036702 DD-A1- 159 289 (43) Date of publication of application: US-A1-2004 043 069 US-A1-2005 042 285 05.12.2012 Bulletin 2012/49 US-A1-2006 159 713 (73) Proprietor: Eagle Pharmaceuticals, Inc. · MAAS B: "Stabilitát von

Woodcliff Lake, NJ 07677 (US) Bendamustinhydrochlorid in

Infusionslösungen", DIE PHARMAZIE, GOVI (72) Inventors: VERLAG PHARMAZEUTISCHERVERLAG GMBH, • PALEPU, Nagesh R. ESCHBORN, DE, vol. 49, no. 10,1 January 1994

Southampton, Pennsylvania 18966 (US) (1994-01-01), pages775-777,XP008060268, ISSN: • BUXTON, Philip Christopher 0031-7144

Great Dunmow

Essex CM6 2PB (GB)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

BACKGROUND OF THE INVENTION

[0001] Bendamustine free base is represented by the following structural formula (I)

(I)· [0002] Bendamustine is used in the treatment of a number of cancers including leukemias, Hodgkins disease and multiple myelomas. Bendamustine is the active ingredient of the commercial product Treanda™, a lyophilized powder for reconstitution.

[0003] DD159289 discloses stable injection solutions comprising bendamustine and propylene glycol.

[0004] Bendamustine exhibits rapid degradation upon reconstitution of the lyophilized product. Bendamustine undergoes hydrolysis by direct substitution rather than an addition elimination process due to the presence of the highly labile aliphatic chlorine atoms. Some of the main degradants of bendamustine are the monohydroxy compound known as HP 1 (hydrolysis product 1) and dihydroxy compound HP2 (hydrolysis product 2). The monohydroxy compound appears as the main impurity at Relative Retention Time (RRT) 0.6 and the dihydroxy compound appears as the main impurity at RRT 0.27. Minor peaks appear at RRT 1.2, which are presently unknown.

[0005] The stability af bendamustine in water is measured in hours, and is therefore, not suitable for long-term storage in liquid form. The lyophile possesses good chemical stability. However, reconstitution of the lyophile is clinically inconvenient, taking 15-30 mins with implications of chemical instability. There is a need for ready to use (RTU) bendamustine formulations having enhanced stability.

SUMMARY OF THE INVENTION

[0006] In accordance with the invention there is provided a long-term storage stable non-aqueous liquid bendamustine-containing composition, comprising: a) bendamustine or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable fluid comprising: i) polyethylene glycol, propylene glycol, or mixtures thereof; and ii) a stabilizing amount of an antioxidant.

[0007] It is also disclosed that, the bendamustine-containing compositions include DMSO (dimethyl sulfoxide) as part of the pharmaceutically acceptable fluid included therein. Regardless of the pharmaceutically acceptable fluid included, the amount of bendamustine included in the composition is preferably from about 20 mg/mL to about 60 mg/mL. Still further aspects of the invention include methods of treatment using bendamustine-containing compositions.

[0008] One of the advantages of the inventive liquid compositions is that they have substantially improved long term stability when compared to currently available formulations. For example, the inventive bendamustine compositions are substantially free of impurities after at least about 15 months at a temperature of from about 5 °C to about 25 °C. The inventive form ulations are advantageously ready to use or ready for further dilution. Reconstitution of lyophilized powders is not required.

DETAILED DESCRIPTION OF THE INVENTION

[0009] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this invention belongs. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

[0010] As used herein, RRT is calculated by dividing the retention time of the peak of interest by the retention time of the main peak. Any peak with an RRT <1 elutes before the main peak, and any peak with an RRT >1 elutes after the main peak.

[0011] For purposes of the present invention, "substantially free of impurities" shall be understood to include benda-mustine-containing compositions in which the amount of total impurities is less than about 5%, as calculated on a normalized peak area response ("PAR") basis as determined by high performance liquid chromatography ("HPLC") at a wavelength of 223nm, after a period of about 15 months at a temperature of from about 5°C to about 25°C. The amount of impurities is further calculated as being based upon the original amount bendamustine (or salt thereof) being present in the composition or formulation.

[0012] For purposes of the present invention, a pharmaceutically acceptable fluid is a fluid which is suitable for pharmaceutical use.

[0013] Preferably, the amount of any individual degradant in the inventive compositions does not exceed 2% PAR as determined by FIPLC at a wavelength of 223nm after storage periods of at least about 15 months at a temperature of from about 5°C to about 25°C. In some aspects, the amount of time the inventive compositions demonstrate long term storage stability is at least about 18 months and preferably at least about 2 years when stored under the conditions described herein.

[0014] In accordance with one aspect of the invention there are provided long term storage stable non-aqueous liquid bendamustine-containing compositions including: a) bendamustine or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable fluid including i) PEG, PG or mixtures thereof; and ii) a stabilizing amount of an antioxidant.

[0015] The total impurities in the inventive compositions resulting from the degradation of the bendamustine in the compositions is less than about 5% PAR as determined by HPLC at a wavelength of 223nm after at least about 15 months at a temperature of from about 5 °C to about 25 °C, and thus have long term stability for at least the same period of time or longer. Preferably, the bendamustine-containing compositions demonstrate long term storage stability for at least about 2 years, especially when stored at the lower (refrigerated) temperatures. In one embodiment, the amount of total impurities in the inventive compositions resulting from the degradation of the bendamustine is less than about 3% PAR as determined by HPLC at a wavelength of 223nm after at least about 2 years at a temperature of from about 5 °C to about 25 °C.

[0016] In some aspects of the invention, the bendamustine concentration in the inventive compositions is from about 10 mg/mL to about 100 mg/mL, preferably 20 mg/mL to about 60 mg/mL. Preferably the bendamustine concentration in the inventive compositions is from about 25 mg/mL to about 50 mg/mL, and more preferably from about 30 mg/mL to about 50 mg/mL. It will be understood that compositions containing any useful concentration within the ranges, i.e. 10, 20, 25, 30, 35, 40, 45, 50, 55, 60 ... 100 are contemplated. In other embodiments, the bendamustine concentration in the composition is about 50 mg/mL. In alternative aspects, the amount of bendamustine is outside these ranges but the amounts will be sufficient for single or multiple administrations of dosages generally regarded as effective amounts.

[0017] In one embodiment, the pharmaceutically acceptable fluid is propylene glycol (PG) or polyethylene glycol (PEG). In other embodiments of the invention however, the pharmaceutically acceptable fluid is a mixture of PEG and PG. For example, the pharmaceutically acceptable fluid can include about 50% PEG and about 50% PG. Alternatively, pharmaceutically acceptable fluid includes about 95% PEG and about 5% PG. The amount of PEG and PG can also be varied within the ranges, i.e. the ratio of PEG:PG in the pharmaceutically acceptable fluid can range from about 95:5 to about 50:50. Within this range, is a pharmaceutically acceptable fluid containing about 75% PEG and about 25% PG, and preferably 80% PEG and 20% PG. In another embodiment, a pharmaceutically acceptable fluid can include about 85% PEG and about 15% PG while another preferred pharmaceutically acceptable fluid includes about 90% PEG and about 10% PG. The molecular weight of the PEG will be within the range of pharmaceutically acceptable weights although PEG 400 is preferred in many aspects of the invention.

[0018] Without meaning to be bound by any theory or hypothesis, the hydroxide of the polyethylene glycol molecule is less reactive than the hydroxides of propylene glycol. As a result, the ester forms at a slower rate in polyethylene glycol than propylene glycol and the resulting bendamustine degradants are unexpectedly and substantially reduced over extended periods of time when PEG is a substantial part of the pharmaceutically acceptable fluid.

[0019] The bendamustine-containing compositions according to the invention include a stabilizing amount of an antioxidant. For purposes of the present invention, "stabilizing amount" shall be understood to include those amounts which increase or enhance the stability of the bendamustine in the compositions described herein. The presence of one or more antioxidants described herein thus contributes, at least in part to the long term stability of the composition. Within this guideline, suitable antioxidant concentrations in the compositions can range from about 2.5 mg/mL to about 35 mg/mL, and preferably from about 5 mg/mL to about 20 mg/mL or from about 10 mg/mL to about 15 mg/mL. In some other embodiments, the concentration of the antioxidant in the bendamustine-containing composition is about 5 mg/mL.

[0020] Suitable antioxidants for inclusion include those which are pharmaceutically acceptable for use in human and veterinary formulations although not limited to those currently regarded as safe by any regulatory authority. For example, the antioxidant can be selected from among lipoic acid, thioglycerol (also known as monothioglycerol) and analogs thereof, propyl gallate, methionine, cysteine, metabisulfites, sodium formaldehyde sulfoxylate, phenol-containing aromatic and aliphatic compounds, dihydrolipoic acid and mixtures of theforegoing. Preferably, the antioxidant is thioglycerol, lipoic acid or a mixture thereof. Some particularly preferred embodiments of the invention include thioglycerol.

[0021] In view of the foregoing, some preferred long term storage stable bendamustine-containing compositions in accordance with the invention compositions include: I. a) bendamustine or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable fluid including i) polyethylene glycol and propylene glycol; and ii) a stabilizing amount of thioglycerol; or II. a) about 50 mg/mL bendamustine or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable fluid including i) about 90% PEG and about 10% PG; and ii) about 2.5 mg/mL thioglycerol.

[0022] Each of these compositions have the same stability profiles already described, i.e. having less than about 5% total impurities, PAR as determined by HPLC at a wavelength of 223nm, after at least about 15 months of storage at a temperature of from about 5 °C to about 25 °C.

[0023] Also disclosed are long term storage stable bendamustine-containing compositions, including: a) bendamustine or a pharmaceutically acceptable salt thereof; b) a pharmaceutically acceptable fluid including one or more of the following: PG, ethanol, PEG, benzyl alcohol and glycofurol; and c) a stabilizing amount of a chloride salt.

[0024] These compositions also have the low levels of impurities and long term stability mentioned herein. Preferred pharmaceutically acceptable fluids include PG, PEG or ethanol in this embodiment of the invention. Preferably, the PEG is PEG 400. If desired, glycerin and/or 88% (w/w) lactic acid can be added to the pharmaceutically acceptable fluid.

[0025] Suitable chloride salts include but are not limited to organic chloride salts, sodium chloride, choline chloride, hydrochloride salts of amino acids and mixtures thereof. Thus, as will be appreciated by those of ordinary skill, one can select from among a number of suitable chloride salts and include all such chloride salts that are capable of being included in bendamustine-containing formulations for extended periods without having a deleterious effect on the drug. In one embodiment of the invention, the chloride salt concentration is from about 10 to about 300 mg/mL. In another embodiment, the chloride salt concentration is from about 50 to about 215 mg/mL. In one preferred embodiment, the chloride salt concentration is about 215 mg/mL.

[0026] Also disclosed are long term storage stable bendamustine-containing compositions, including: a) bendamustine or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable fluid including DMSO.

[0027] These compositions also have the low levels of impurities and long term stability mentioned herein. In some aspects, the bendamustine concentration in these compositions is from about 10 mg/mL to about 100 mg/mL. Preferably, the bendamustine concentration is from about 20 mg/mL to about 50 mg/mL, more preferably from about 25 mg/mL to about 50 mg/mL. In an alternative disclosure, the bendamustine concentration is about 50 mg/mL.

[0028] Another embodiment of the invention provides methods of treating cancer in mammals. The methods include administering to a mammal in need thereof an effective amount of one of the bendamustine-containing compositions described herein. Since the active ingredient portion of the inventive composition is an FDA-approved drug, those of ordinary skill will recognize that the doses of bendamustine employed in this aspect of the invention will be similar to those employed in any treatment regimens designed for bendamustine as marketed under the trade name TREANDA. The patient package insert containing dosing information is incorporated herein by reference. The methods of treatment also include administering the inventive formulations for any purpose or physical condition for which bendamustine has been indicated as being useful.

[0029] Also disclosed are methods of preparing bendamustine-containing compositions described herein. The methods include reconstituting lyophilized bendamustine in a pharmaceutically acceptable fluid containing one of the following: A) i) PEG, PG or mixtures thereof; and ii) a stabilizing amount of an antioxidant; B) i) one or more of PG, ethanol, PEG, benzyl alcohol and glycofurol; and ii) a stabilizing amount of a chloride salt; or C) DMSO.

[0030] The steps are carried out under pharmaceutically acceptable conditions for sterility and manufacturing.

[0031] Also disclosed are methods of controlling or preventing the formation of impurities in bendamustine-containing compositions during long term storage. The methods include combining an amount of bendamustine or a pharmaceutically acceptable salt thereof with a sufficient amount of a pharmaceutically acceptable fluid containing one of the following: A) i) PEG, PG or mixtures thereof; and ii) a stabilizing amount of an antioxidant; B) i) one or more of PG, ethanol, PEG, glycofurol and benzyl alcohol; and ii) a stabilizing amount of a chloride salt; or C) DMSO.

[0032] Further optional steps in accordance therewith include transferring one or more pharmaceutically acceptable doses of the formulations into a suitable sealable container and storing the sealed container at a temperature of from about 5 °C to about 25 °C. As a result of carrying out these steps, it is possible to control or substantially prevent the formation of impurities which otherwise occur with bendamustine-containing compositions during long term storage so that the artisan is provided with bendamustine-containing formulations having less than about 5 % total impurities PAR as determined by HPLC at a wavelength of 223nm, after at least about 15 months of storage at a temperature of from about 5 °C to about 25 °C.

[0033] The compositions of the present invention can be packaged in any suitable sterile vial or container fit for the sterile storage of a pharmaceutical such as bendamustine. Suitable containers can be glass vials, polypropylene or polyethylene vials or other special purpose containers and be of a size sufficient to hold one or more doses of bendamustine.

[0034] Also disclosed are kits containing lyophilized bendamustine or a pharmaceutically acceptable salt thereof in a first container or vial; and, in a second container, a sufficient amount of a pharmaceutically acceptable fluid such as those described herein, i.e. one of the following: A) i) PEG, PG or mixtures thereof; and ii) a stabilizing amount of an antioxidant; B) i) one or more of PG, ethanol, PEG, glycofurol and benzyl alcohol; and ii) a stabilizing amount of a chloride salt; or C) DMSO.

[0035] The amount of fluid which is sufficient is an amount which allows the bendamustine to be dissolved or dispersed to a degree which renders the liquid composition ready for use.

[0036] As will be appreciated by those of ordinary skill, the kit will contain other pharmaceutically necessary materials for storing and/or administering the drug, including instructions for storage and use, additional diluents, if desired, etc.

EXAMPLES

[0037] The following examples serve to provide further appreciation of the invention but are not meant in any way to restrict the effective scope of the invention.

Reference Example 1 [0038] Bendamustine-containing compositions were prepared by dissolving bendamustine HCI to a concentration of 10mg/ml in one of ethanol, propylene glycol and benzyl alcohol as indicated in Table 1 below. 215 mg/ml of choline chloride was added in half of the samples as a source of soluble chloride ions. The samples were maintained at 40 °C and analyzed periodically for drug content and total impurities. The results obtained are presented in Table 1.

Table 1 - Stability of Bendamustine HCI

[0039] As shown in Table 1, the bendamustine formulations are very stable in solutions containing solvent and chloride salt. Table 1 shows that bendamustine, when dissolved at a concentration of about 10 mg/mL, in a pharmaceutically acceptable fluid, such as ethanol and propylene glycol, and containing a stabilizing amount of a chloride salt, such as choline chloride, had less than about 5% after at least 7 days storage at 40 °C.

[0040] Thedata presented in Table 1 translates to bendamustine-containing compositions including a pharmaceutically acceptable fluid and a stabilizing amount of a chloride salt having a shelf life of at least about 15 months at 5 °C and 25 °C.

[0041] The sample including ethanol alone exhibited more than 6.5 total degradants after 7 days storage at 40 °C. The sample including benzyl alcohol alone exhibited more than 7.5% total degradants after 7 days storage at 40 °C. Bendamustine-containing compositions with such high levels of degradation would not be suitable for long-term storage.

Reference Example 2 [0042] Bendamustine-containing compositions were prepared by dissolving bendamustine HCI to a concentration of 10mg/ml in DMSO. The samples were maintained at 40 °C and analyzed periodically for drug content and impurity profile. The results obtained are presented in Table 2.

Table 2 - Stability of Bendamustine HCI in DMSO

[0043] Table 2 shows that bendamustine, when dissolved in DMSO, had substantially no increase in total degradants. The data presented in Table 2 translates to bendamustine-containing compositions including DMSO having a shelf life of at least about 15 months at 5 °C and 25 °C. In fact, such compositions are expected to have long term stability for periods beyond 15 months, i.e. up to 2 years or greater.

Example 3 [0044] Bendamustine-containing compositions were prepared by dissolving bendamustine HCI to a concentration of 20 mg/ml in polyethylene glycol 400 and 5 mg/ml of lipoic acid was added as a stabilizing antioxidant as indicated in Table 3 below. The samples were maintained at 40 °C or 25 °C and analyzed after 15 days for drug content and impurities. The results obtained are presented in Table 3.

Table 3: Stability of Bendamustine (20mg/ml) in PEG 400 and Antioxidants

[0045] As shown in Table 3, bendamustine, when dissolved in a pharmaceutically acceptable fluid, such as polyethylene glycol, in the presence of a stabilizing amount of an antioxidant, such as lipoic acid, had substantially no increase in total degradants after a period of 15 days. The data presented in Table 3 translates to bendamustine-containing compositions including a pharmaceutically acceptable fluid and a stabilizing amount of an antioxidant having a shelf life of at least about 15 months at 5 °C and 25 °C.

[0046] The sample including PEG alone, on the other hand, which did not contain an antioxidant, did not exhibit stabilizing effects at 40 °C. This sample had more than 40% more total impurities than the sample including lipoic acid. Bendamustine-containing compositions with such high levels of total impurities would not be suitable for long-term storage.

Example 4 [0047] Bendamustine-containing compositions were prepared by dissolving bendamustine HCI to a concentration of 50 mg/ml in 90% polyethylene glycol 400 and 10% propylene glycol. 5 mg/ml of thioglycerol, α-lipoicacid ordihydrolipoic acid was added as a stabilizing antioxidant as indicated in Table 4 below. The samples were maintained at 40 °C and analyzed after 15 days or one month for drug content and impurity profile as indicated in Table 4 below. The results obtained are presented in Table 4.

Table 4: Stability of Bendamustine (50mg/ml) in 90% PEG 400, 10% Propylene Glycol and Antioxidant

[0048] As shown in Table 4, bendamustine, when dissolved in a pharmaceutically acceptable fluid, such as a combination of polyethylene glycol and propylene glycol, in the presence of a stabilizing amount of an antioxidant, such as thioglycerol, α-lipoic acid or dihydrolipoic acid, had substantially no increase in total degradants after a period of 1 month. This data supports the position that bendamustine-containing compositions according to the invention have a shelf life of at least about 2 years when stored at temperatures between 5 °C and 25 °C.

Example 5 [0049] Bendamustine-containing compositions were prepared by dissolving bendamustine HCI to a concentration of 50 mg/ml in a mixture of polyethylene glycol 400 and propylene glycol as indicated in Table 5 below. 5 mg/ml of lipoic acid was added as a stabilizing antioxidant. The samples were maintained at 40 °C, 25 °C and 5 °C and analyzed after 1 week, 15 days or one month for drug content and impurity profile as indicated in Table 5 below. The results obtained are presented in Table 5.

Table 5: Stability of Bendamustine (50 mg/ml) and Lipoic Acid (5 mg/ml) in PEG400 and Propylene glycol

(continued)

[0050] As shown in Table 5, bendamustine, when dissolved in certain mixtures of presented in Table 5 translates to bendamustine-containing compositions having a shelf life of at least about 2 years when stored at temperatures between 5 °C and at 25 °C.

Example 6 [0051] Bendamustine-containing compositions were prepared by dissolving bendamustine HCI to a concentration of 50 mg/ml in 90% polyethylene glycol 400 and 10% propylene glycol and a-lipoic acid was added as a stabilizing antioxidant as indicated in Table 6 below. The samples were maintained at 40 °C, 25 °C and 5 °C and analyzed for drug content and impurity profile as indicated in Table 6 below. The results obtained are presented in Table 6.

Table 6: Stability of Bendamustine in 90% PEG 400, 10% PG and a-lipoic acid

[0052] The data reported in Table 6 along with the data in Table 5 demonstrates that bendamustine solutions are stable when dissolved in mixtures of PEG and PG and 5-15mg/mL a-lipoic acid. As shown in Table 6, bendamustine, when dissolved in combinations of polyethylene glycol and propylene glycol, in the presence of a stabilizing amount of lipoic acid, had less than 3% increase in total degradants after a period of 3 months at 40 °C. Additionally, the same compounds had substantially no increase in total degradants after a period of 6-12 months at 5 °C and 25 °C. The data corresponds to bendamustine solutions being stable under ambient or refrigerated storage conditions for well in excess of 2 years, and thus long term stable.

Example 7 [0053] Bendamustine-containing compositions were prepared by dissolving bendamustine HCI to a concentration of 50 mg/ml in 90% polyethylene glycol 400 and 10% propylene glycol. 2.5 mg/ml of thioglycerol was added as an antioxidizing agent. The samples were maintained at 40 °C and 25 °C and analyzed for drug content and impurity profile as indicated in Table7 below. The results obtained are presented in Table 7.

Table 7: Stability of Bendamustine in 90% PEG 400, 10% PG and Thioglycerol

[0054] The stability is similar to that of a-lipoic acid samples in Example 6 above. As shown in Table 7, bendamustine, when dissolved in a combination of polyethylene glycol and propylene glycol, and a stabilizing amount of thioglycerol, had less than 3% increase in total degradants after a period of 3 months at 40 °C. Additionally, the same compounds had substantially no increase in total degradants after a period of 6 months at 25 °C. The data reported supports the conclusion that these bendamustine solutions are stable under ambient or refrigerated storage conditions for about 2 years.

Example 8 [0055] Bendamustine-containing compositions were prepared by dissolving bendamustine HCI to a concentration of 50 mg/ml in 85% PEG 400 and 15% PG in the presence of 5 mg/ml of thioglycerol. The samples were maintained at 40 °C and 25 °C and analyzed for drug content and impurity profile as indicated in Table 8 below. The results obtained are presented in Table 8.

Table 8: Stability of Bendamustine in 85% PEG 400, 15% PG and Thioglycerol

[0056] The stability is similar to that of thioglycerol samples in Example 7 above. As reported in Table 8, total impurities did not exceed 2% at 40 °C or 25°C storage over one month, or at 25 °C and 5 °C storage after three months. The data reported in Table 8 supports the conclusion that these bendamustine solutions are stable under ambient or refrigerated storage conditions for at least about 2 years if not longer.

Claims 1. A long term storage stable non-aqueous liquid bendamustine-containing composition, comprising: a) bendamustine or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable fluid comprising: i) polyethylene glycol, propylene glycol, or mixtures thereof; and ii) a stabilizing amount of an antioxidant. 2. The long term storage stable non-aqueous liquid bendamustine-containing composition of claim 1, wherein the bendamustine concentration is from 20 mg/mL to 60 mg/mL, preferably from 25 mg/mL to 50 mg/mL. 3. The long term storage stable non-aqueous liquid bendamustine-containing composition of any one of previous claim, wherein the pharmaceutically acceptable fluid comprises 95% polyethylene glycol and 5% propylene glycol. 4. The long term storage stable non-aqueous liquid bendamustine-containing composition of any one of claim 1 or 2, wherein the pharmaceutically acceptable fluid comprises 90% polyethylene glycol and 10% propylene glycol. 5. The long term storage stable non-aqueous liquid bendamustine-containing composition of any one of claim 1 or 2 , wherein the pharmaceutically acceptable fluid comprises 85% polyethylene glycol and 15% propylene glycol. 6. The long term storage stable non-aqueous liquid bendamustine-containing composition of any of the previous claims, wherein the antioxidant is selected from the group consisting of thioglycerol, monothioglycerol, lipoic acid, propyl gallate, methionine, cysteine, metabisulfites, sodium formaldehyde sulfoxylate, phenol-containing aromatic and aliphatic compounds and dihydrolipoic acid. 7. The long term storage stable non-aqueous liquid bendamustine-containing composition of any of the previous claims, wherein the stabilizing amount of the antioxidant is from 2.5 mg/mL to 35 mg/mL. 8. The long term storage stable non-aqueous liquid bendamustine-containing composition of claim 7, wherein the stabilizing amount of the antioxidant is from 5 mg/mL to 20 mg/mL. 9. The long term storage stable non-aqueous liquid bendamustine-containing composition of claim 1, comprising: a) bendamustine or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable fluid comprising i) 90% polyethylene glycol and 10% propylene glycol; and ii) a stabilizing amount of thioglycerol. 10. The long term storage stable non-aqueous liquid bendamustine-containing composition of claim 1, comprising: a) bendamustine or a pharmaceutically acceptable salt thereof at a concentration of 50 mg/mL; and b) a pharmaceutically acceptable fluid comprising i) 90% polyethylene glycol and 10% propylene glycol; and ii) thioglycerol at a concentration of 2.5 mg/mL. 11. The long term storage stable non-aqueous liquid bendamustine-containing composition of any of the previous claims, for use in the treatment of cancer in mammals. 12. The long term storage stable non-aqueous liquid bendamustine-containing composition of claim 1, wherein the pharmaceutically acceptable fluid comprises 80% polyethylene glycol and 20% propylene glycol. 13. The long term storage stable non-aqueous liquid bendamustine-containing composition of claim 1, wherein the pharmaceutically acceptable fluid comprises 75% polyethylene glycol and 25% propylene glycol. 14. The long term storage stable non-aqueous liquid bendamustine-containing composition of claim 1, wherein the pharmaceutically acceptable fluid comprises 50% polyethylene glycol and 50% propylene glycol.

Patentanspriiche 1. Langzeitig lagerstabile, nichtwássrige, fliissige, Bendamustin enthaltende Zusammensetzung umfassend: a) Bendamustin Oder ein pharmazeutisch akzeptables Salz davon; und b) ein pharmazeutisch akzeptables Fluid umfassend: i) Polyethylenglykol, Polypropylenglykol Oder Mischungen davon; und ii) eine stabilisierende Menge eines Antioxidationsmittels. 2. Langzeitig lagerstabile, nichtwássrige, fliissige, Bendamustin enthaltende, Zusammensetzung nach Anspruch 1, wobei die Bendamustinkonzentration 20 mg/ml bis 60 mg/ml, bevorzugt 25 mg/ml bis 50 mg/ml betrágt. 3. Langzeitig lagerstabile, nichtwássrige, fliissige, Bendamustin enthaltende Zusammensetzung nach irgendeinem vorhergehenden Anspruch, wobei das pharmazeutisch akzeptable Fluid 95 % Polyethylenglykol und 5 % Propylen-glykol umfasst. 4. Langzeitig lagerstabile, nichtwássrige, fliissige, Bendamustin enthaltende Zusammensetzung nach einem der An-spriiche 1 Oder 2, wobei das pharmazeutisch akzeptable Fluid 90 % Polyethylenglykol und 10 % Polypropylenglykol umfasst. 5. Langzeitig lagerstabile, nichtwássrige, flüssige, Bendamustin enthaltende Zusammensetzung nach einem dér An-sprüche 1 oder 2, wobei das pharmazeutisch akzeptable Fluid 85 % Polyethylenglykol und 15 % Polypropylenglykol umfasst. 6. Langzeitig lagerstabile, nichtwássrige, flüssige, Bendamustin enthaltende Zusammensetzung nach irgend einem dér vorhergehenden Ansprüche, wobei das Antioxidationsmittel aus dér Gruppé ausgewáhlt wird bestehend aus Thioglycerin, Monothioglycerin, Liponsáure, Propylgallat, Methionin, Cystein, Metabisulfiten, Natriumformaldehyd-sulfoxylat, phenolhaltigen aromatischen und aliphatischen Verbindungen und Dihydroliponsáure. 7. Langzeitig lagerstabile, nichtwássrige, flüssige, Bendamustin enthaltende Zusammensetzung nach einem dér vorhergehenden Ansprüche, wobei die stabilisierende Menge des Antioxidationsmittels 2,5 mg/ml bis 35 mg/ml betrágt. 8. Langzeitig lagerstabile, nichtwássrige, flüssige, Bendamustin enthaltende Zusammensetzung nach Anspruch 7, wobei die stabilisierende Menge des Antioxidationsmittels 5 mg/ml bis 20 mg/ml betrágt. 9. Langzeitig lagerstabile, nichtwássrige, flüssige, Bendamustin enthaltende Zusammensetzung nach Anspruch 1, umfassend: a) Bendamustin oder ein pharmazeutisch akzeptables Salz davon; und b) ein pharmazeutisch akzeptables Fluid umfassend i) 90 % Polyethylenglykol und 10 % Polypropylenglykol; und ii) eine stabilisierende Menge von Thioglycerin. 10. Langzeitig lagerstabile, nichtwássrige, flüssige, Bendamustin enthaltende Zusammensetzung nach Anspruch 1, umfassend: a) Bendamustin oder ein pharmazeutisch akzeptables Salz davon in einer Konzentration von 50 mg/ml; und b) ein pharmazeutisch akzeptables Fluid umfassend i) 90 % Polyethylenglykol und 10 % Polypropylenglykol; und ii) Thioglycerin in einer Konzentration von 2,5 mg/ml. 11. Langzeitig lagerstabile, nichtwássrige, flüssige, Bendamustin enthaltende Zusammensetzung nach irgendeinem dér vorhergehenden Ansprüche zűr Verwendung bei dér Behandlung von Krebs in Sáugern. 12. Langzeitig lagerstabile, nichtwássrige, flüssige, Bendamustin enthaltende Zusammensetzung nach Anspruch 1, wobei das pharmazeutisch akzeptable Fluid 80 % Polyethylenglykol und 20 % Polypropylenglykol umfasst. 13. Langzeitig lagerstabile, nichtwássrige, flüssige, Bendamustin enthaltende Zusammensetzung nach Anspruch 1, wobei das pharmazeutisch akzeptable Fluid 75 % Polyethylenglykol und 25 % Polypropylenglykol umfasst. 14. Langzeitig lagerstabile, nichtwássrige, flüssige, Bendamustin enthaltende Zusammensetzung nach Anspruch 1, wobei das pharmazeutisch akzeptable Fluid 50 % Polyethylenglykol und 50 % Polypropylenglykol umfasst.

Revendications 1. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine, comprenant: a) de la bendamustine ou un sel pharmaceutiquement acceptable de celle-ci ; et b) un liquide pharmaceutiquement acceptable comprenant: i) du polyéthyléne glycol, du propyléne glycol ou des mélanges de ceux-ci ; et ii) une quantité stabilisatrice d’un antioxydant. 2. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon la revendi-cation 1, dans laquelle la concentration en bendamustine est comprise entre 20 mg/ml et 60 mg/ml, de préférence entre 25 mg/ml et 50 mg/ml. 3. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon I’une quel-conque des revendications précédentes, dans laquelle le liquide pharmaceutiquement acceptable comprend 95 % de polyéthyléne glycol et 5 % de propyléne glycol. 4. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon I’une quel-conque de la revendication 1 ou 2, dans laquelle le liquide pharmaceutiquement acceptable comprend 90 % de polyéthyléne glycol et 10 % de propyléne glycol. 5. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon I’une quel-conque de la revendication 1 ou 2, dans laquelle le liquide pharmaceutiquement acceptable comprend 85 % de polyéthyléne glycol et 15 % de propyléne glycol. 6. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon I’une quel-conque des revendications précédentes, dans laquelle l’antioxydant est choisi dans le groupe constitué par le thioglycérol, le monothioglycérol, l’acide lipoíque, le gallate de propyle, la méthionine, la cystéine, les métabisulfites, le sulfoxylate formaldéhyde de sodium, les composés aromatiques et aliphatiques contenant du phénol et l’acide dihydrolipoíque. 7. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon l’une quel-conque des revendications précédentes, dans laquelle la quantité stabilisatrice de l’antioxydant est comprise entre 2,5 mg/ml et 35 mg/ml. 8. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon la revendication 7, dans laquelle la quantité stabilisatrice de l’antioxydant est comprise entre 5 mg/ml et 20 mg/ml. 9. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon la revendication 1, comprenant: a) de la bendamustine ou un sel pharmaceutiquement acceptable de celle-ci; et b) un liquide pharmaceutiquement acceptable comprenant: i) 90 % de polyéthyléne glycol et 10 % de propyléne glycol ; et ii) une quantité stabilisatrice de thioglycérol. 10. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon la revendication 1, comprenant: a) de la bendamustine ou un sel pharmaceutiquement acceptable de celle-ci á une concentration de 50 mg/ml; et b) un liquide pharmaceutiquement acceptable comprenant: i) 90 % de polyéthyléne glycol et 10 % de propyléne glycol ; et ii) du thioglycérol á une concentration de 2,5 mg/ml. 11. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon l’une quel-conque des revendications précédentes, pour une utilisation dans le traitement de cancer chez les mammiféres. 12. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon la revendication 1, dans laquelle le liquide pharmaceutiquement acceptable comprend 80 % de polyéthyléne glycol et 20 % de propyléne glycol. 13. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon la revendication 1, dans laquelle le liquide pharmaceutiquement acceptable comprend 75 % de polyéthyléne glycol et 25 % de propyléne glycol. 14. Composition liquide non aqueuse stable au stockage á long terme contenant de la bendamustine selon la revendication 1, dans laquelle le liquide pharmaceutiquement acceptable comprend 50 % de polyéthyléne glycol et 50 % de propyléne glycol.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description • DD 159289 [0003]

Claims

B£NDA»ÜSZ1 ÍN K«S2ERBJÉS8! o'VC' - m - V'-AVO U Hosszú Kíötsrtamö tÉÉ§$$ is ;li, néföv§»^ o :||p^zPÍ tg^roa: é. mmmm^ *m $e§a; és Pl- gyógyászáig élfogadhalö yyadék, smoíy s fcö*a&s?ákaÍ tsítsfmszzs: i) sxsatííangtlkoí. ptopitéogtikoi. vagy ozsk ksveféksí; ;#§: in ant-oxldáns stabilizáló maOiSylségbmt. 2 Az > Ιρν'^ροο; szsnml hosszo söteta&ú nm-wm an-v ,; bViOdamasztin κ^οοηΡοοό a 20 mg/mt és οδ mg/mt közti isiiományban. stonyoser· a 25 mg/fni és §0 íngiml koz* tartomanyt-ao van,
3, Az 1 vagy 2 '§éi>>{yvRÍ szmiab, hosszú időtartamú tárolásáét is stafck, ftém-v«$e$ íotysdéhöl. .ΜβΙ^Λ sompozido, ahd a gyugyaszafc-sg etfegaéhasó folyadék tartalmaz §5% gpíletiiéngltkoií ss 5% pfopifobpketk 4 Az ? vagy 2. igénypont xzsnns hössztnöötSfíSi'ns tarolssséhs stabil, nosn-vizes, öenóamuszsin-#rt|tötO :köPM2idö.: 3poi® gyogyaszataag eíiogssln&tö totyaáék Isilstfo.a.? 30% potleblpngtikott és 10% píoplléngtikoit 5 Az 1 vagy 2 igénypont szidok. hosszé időtartamé íérelásnát is stabil. nenvvlzos kompöz-.öö, phot a gyögyészaNag ^fogadható folyadék tartalmaz ÖS% polcöiéssgllkott.éx 15% propiíé?$gsköit.
6, Az t-;> ;gSnypon|c.^ curm-iyAa szprínö szánná, n&xszu időtartamú is-oléimát t$ xtsöA osm-vizes folyadékos. dsnúitipsztls·· tartalmú kpmsoifotö altot az snüo?:dánx o követksz% kczin véisszihato fo. kogkcsdn. n-önokogtscann, sponsav tífoöio adop pmpii'g&tiát, mebon-ü ciszfoin matsbiszdiiíok f53tm.”i'4rmíSfoafod-szuiíö,*?aL fottot-foítAfouj «mo-ss es adós vegyisafo*, ss .d&sdraupaassv.·; ? Az t.a rgonyponk-k t ρ^γΑδ szarlak. bosszú iúötetamu foroiésnái is sfobsl, ofem-sis^s-fe?y^d^to§:<;: kornpozlosé ahol a; sneoxiöéAS dstdizdb msnoysxégs a 2.5 mgnní és 35 mg/mt közötti iséoofonyban van 5 A ?. igénypont βζοπηίί szadd. hüsssü döfoifomú tarolásnál is stabil. nosn-vizes folyadékos, btvtdamusztfoAartaimö kompozíció, ahd az amfoxsdfcn sipbiiizalé mennyisége az 5 mg/ml és 20 mgíml közöd taooményp# vsa
9, Az 1 igéhypónl ókéttpéAöössxO iölsúsíRűiá^ilsnsi ;s sfoölk nonwizes folyadékos, öer#mgs#>#tfotma kompozíció, smaiy asóv&Azssksí%?tslmszss: a) bendamtssztiu vagy gyógyászatiig; sifogsdhsfo ssosa as Pl gyögyáxzahfog ^fogadható folyadék, arody a Kovt^sezCNetilattafeaizza; II §0% poilötlténpiikcl as 1 öl; pspprsgíikd. és Λ"οζ' t i,'-, :^ " d vné tdi :1ör ΜΦ- iPlPyppnt Iplioin yn#i iiatlgmtiitliml^Pái Is stabil, tsam-vlzaa foiyadiips, amely o köystKazökst ösflgsma»; i|. bsndamnsztln vagy gyógyssíahlég otíogébiéPöp ös öl gyogyaszaMs^ oitogadbsiö folyzhlPk, it <m> pollstyóstgt'hoi és 10% popléofköl la «} liogsicoan g.ónKl/a^ ΚΟΡοορρΙοΐόΐΜ, 11 Az M0. igénypöítfok b&n»sy*e szérimi, Péészö ísroiásísál is:issra^: Isítsvnó kombozkvö gikaisTiazasia kézosaséré snstttsokkhs'i
12, Az 1 igénypont szenstk hosszé idotmtanvi tarolssnái * sttk-v i^em-vizaa fc^yaOékns teöamtipWéflaimú '^t^|gör 3hi>; a élkspSHSSS ágyasak :s;ta:in«i §o% poUenlénghkoü és 20¾ pmpitasskksil 13; At Is Igépfpfit saakaS, kosiak ^gf^alöklrölásísé) is ssékl asísvvfes tólyapskös.: Sikk a gypgyástaiap oiispONíkÓ fgiyaölk isilakpsk f|%; pösaiéspiiMi és 2S% pippilsopkoft: lé; A? lápsypsnt;s|6sni lioss|i ;dé;ar:a;na tá-oiásas? is sSÉSL n-sawfeas folyidéfm sasaaswIssiS'isaakas ksmpssi$iás aSsi a gysaysstslaf ellyiaöSáiáföpélk tskskpM:§s% psiioiéspsoikésSöt; pasp&iopkofi: